Description

Antifol (Pemetrexed Injection) is a prescription chemotherapy medicine containing Pemetrexed, an antifolate antineoplastic agent used to treat specific types of cancer. It works by blocking enzymes that cancer cells need to produce DNA and RNA, slowing or stopping the growth of rapidly dividing cancer cells. Pemetrexed is commonly used alone or in combination with other anticancer medicines depending on the type and stage of cancer. Uses of Antifol (Pemetrexed Injection) Non-squamous Non-Small Cell Lung Cancer (NSCLC) Malignant Pleural Mesothelioma Maintenance treatment for advanced NSCLC after initial chemotherapy Advanced or metastatic lung cancer in combination with platinum-based chemotherapy and other approved therapies, as recommended by an oncologist. How It Works Pemetrexed inhibits multiple folate-dependent enzymes involved in DNA and RNA synthesis. This prevents cancer cells from growing and multiplying, leading to their destruction while helping to slow disease progression. Administration Given as an intravenous (IV) infusion by a qualified healthcare professional. Treatment is usually administered in 21-day cycles, depending on the patient's condition and treatment plan. Patients are typically prescribed folic acid, vitamin B12, and dexamethasone to reduce the risk of treatment-related side effects. Possible Side Effects Common side effects may include: Fatigue Nausea and vomiting Loss of appetite Mouth sores Low white blood cell count (neutropenia) Anemia Low platelet count Skin rash Increased risk of infection Seek immediate medical attention if severe fever, unusual bleeding, difficulty breathing, or allergic reactions occur. Precautions Use only under the supervision of an experienced oncologist. Regular blood tests and kidney function monitoring are required during treatment. Inform your healthcare provider about all medications and existing medical conditions before starting therapy. Avoid pregnancy during treatment and follow your doctor's advice regarding contraception. Patients with significant kidney impairment may not be suitable candidates for treatment.